331 related articles for article (PubMed ID: 26169371)
1. Broad protection with an inactivated vaccine against primary-isolated lethal enterovirus 71 infection in newborn mice.
Chang J; Li J; Liu X; Liu G; Yang J; Wei W; Zhang W; Yu XF
BMC Microbiol; 2015 Jul; 15():139. PubMed ID: 26169371
[TBL] [Abstract][Full Text] [Related]
2. Clinically isolated enterovirus A71 subgenogroup C4 strain with lethal pathogenicity in 14-day-old mice and the application as an EV-A71 mouse infection model.
Xu Y; Ma S; Zhu L; Huang Z; Chen L; Xu Y; Yin H; Peng T; Wang Y
Antiviral Res; 2017 Jan; 137():67-75. PubMed ID: 27864074
[TBL] [Abstract][Full Text] [Related]
3. Human Enterovirus 71 Protein Displayed on the Surface of Saccharomyces cerevisiae as an Oral Vaccine.
Zhang C; Wang Y; Ma S; Li L; Chen L; Yan H; Peng T
Viral Immunol; 2016 Jun; 29(5):288-95. PubMed ID: 27259043
[TBL] [Abstract][Full Text] [Related]
4. Enterovirus A71 Containing Codon-Deoptimized VP1 and High-Fidelity Polymerase as Next-Generation Vaccine Candidate.
Tsai YH; Huang SW; Hsieh WS; Cheng CK; Chang CF; Wang YF; Wang JR
J Virol; 2019 Jul; 93(13):. PubMed ID: 30996087
[TBL] [Abstract][Full Text] [Related]
5. Development of a full-length cDNA-derived enterovirus A71 vaccine candidate using reverse genetics technology.
Yang YT; Chow YH; Hsiao KN; Hu KC; Chiang JR; Wu SC; Chong P; Liu CC
Antiviral Res; 2016 Aug; 132():225-32. PubMed ID: 27387826
[TBL] [Abstract][Full Text] [Related]
6. EV-A71 vaccine licensure: a first step for multivalent enterovirus vaccine to control HFMD and other severe diseases.
Mao Q; Wang Y; Bian L; Xu M; Liang Z
Emerg Microbes Infect; 2016 Jul; 5(7):e75. PubMed ID: 27436364
[TBL] [Abstract][Full Text] [Related]
7. Impact of genetic changes, pathogenicity and antigenicity on Enterovirus- A71 vaccine development.
Yee PTI; Laa Poh C
Virology; 2017 Jun; 506():121-129. PubMed ID: 28384566
[TBL] [Abstract][Full Text] [Related]
8. A Polysaccharide Purified From
Lin YL; Shih C; Cheng PY; Chin CL; Liou AT; Lee PY; Chiang BL
Front Immunol; 2020; 11():561758. PubMed ID: 33117346
[TBL] [Abstract][Full Text] [Related]
9. Immune responses against enterovirus A71 infection: Implications for vaccine success.
Aw-Yong KL; NikNadia NMN; Tan CW; Sam IC; Chan YF
Rev Med Virol; 2019 Sep; 29(5):e2073. PubMed ID: 31369184
[TBL] [Abstract][Full Text] [Related]
10. Hand, foot and mouth disease and herpangina caused by enterovirus A71 infections: a review of enterovirus A71 molecular epidemiology, pathogenesis, and current vaccine development.
Chang YK; Chen KH; Chen KT
Rev Inst Med Trop Sao Paulo; 2018 Nov; 60():e70. PubMed ID: 30427405
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity, safety, cross-reaction, and immune persistence of an inactivated enterovirus A71 vaccine in children aged from two months to 11 years in Taiwan.
Huang LM; Chiu CH; Chiu NC; Lin CY; Li MT; Kuo TY; Weng YJ; Hsieh EF; Tai IC
Vaccine; 2019 Mar; 37(13):1827-1835. PubMed ID: 30803843
[TBL] [Abstract][Full Text] [Related]
12. Is a multivalent hand, foot, and mouth disease vaccine feasible?
Klein M; Chong P
Hum Vaccin Immunother; 2015; 11(11):2688-704. PubMed ID: 26009802
[TBL] [Abstract][Full Text] [Related]
13. Recent development of enterovirus A vaccine candidates for the prevention of hand, foot, and mouth disease.
Fang CY; Liu CC
Expert Rev Vaccines; 2018 Sep; 17(9):819-831. PubMed ID: 30095317
[TBL] [Abstract][Full Text] [Related]
14. Immunological and biochemical characterizations of coxsackievirus A6 and A10 viral particles.
Liu CC; Guo MS; Wu SR; Lin HY; Yang YT; Liu WC; Chow YH; Shieh DB; Wang JR; Chong P
Antiviral Res; 2016 May; 129():58-66. PubMed ID: 26899790
[TBL] [Abstract][Full Text] [Related]
15. Establishment of an animal challenge model as a potency assay for an inactivated Enterovirus Type 71 vaccine.
Wang KT; Lin SJ; Wang HC; Chen PC; Lin JJ; Chiang JR; Chang CL; Shih DY; Lo CF; Wang DY
Biologicals; 2016 Jul; 44(4):183-190. PubMed ID: 27068365
[TBL] [Abstract][Full Text] [Related]
16. Formalin-inactivated vaccine provokes cross-protective immunity in a mouse model of human enterovirus 71 infection.
Bek EJ; Hussain KM; Phuektes P; Kok CC; Gao Q; Cai F; Gao Z; McMinn PC
Vaccine; 2011 Jun; 29(29-30):4829-38. PubMed ID: 21550375
[TBL] [Abstract][Full Text] [Related]
17. Protective effect of enterovirus‑71 (EV71) virus‑like particle vaccine against lethal EV71 infection in a neonatal mouse model.
Cao L; Mao F; Pang Z; Yi Y; Qiu F; Tian R; Meng Q; Jia Z; Bi S
Mol Med Rep; 2015 Aug; 12(2):2473-80. PubMed ID: 25936344
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and safety of an inactivated enterovirus A71 vaccine in children 3-6 years and 2-35 months of age- an open-label, randomized phase IIb clinical trial.
Hung MC; Cho CY; Chen CJ; Lai CC; Wu KG
Vaccine; 2019 Sep; 37(37):5559-5566. PubMed ID: 31399275
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and performance of an enterovirus 71 virus-like-particle vaccine in nonhuman primates.
Lim PY; Hickey AC; Jamiluddin MF; Hamid S; Kramer J; Santos R; Bossart KN; Cardosa MJ
Vaccine; 2015 Nov; 33(44):6017-24. PubMed ID: 26271825
[TBL] [Abstract][Full Text] [Related]
20. The stability and immunogenicity of formalin-inactivated Enterovirus A71 whole virion vaccine after ten years of low temperature storage.
Shen YS; Chow YH; Fang CY; Wu SR; Chen CH; Huang MH; Liao CL; Chiang JR; Liu CC
J Microbiol Immunol Infect; 2023 Dec; 56(6):1121-1128. PubMed ID: 37919172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
